SCHEMBL3586375

SCHEMBL3586375

O=C(O)c1nc(Cl)ccc1NC1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 6/20 0.42
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
P2RX7 Q99572 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 1/20 0.35
GRIK1 P39086 1/20 0.35
GRIA2 P42262 1/20 0.35
MELK Q14680 1/20 0.35
CISD1 Q9NZ45 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA7 P43166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16516594 0.76 HCAR3 (0.43) HCAR3ALDH1A1MEN1KMT2ACISD1
SCHEMBL30473132 0.76 ALDH1A1 (0.40) HCAR3ALDH1A1MEN1GAAKMT2A
SCHEMBL3577408 0.76 ALDH1A1 (0.40) HCAR3ALDH1A1MEN1GAAKMT2A
SCHEMBL16878622 0.74 HCAR3 (0.41) HCAR3MELKSLC6A12
SCHEMBL3576469 0.72 MAPT (0.44) HCAR3L3MBTL1ALDH1A1MEN1GAA
Clopyralid SCHEMBL29371357 0.70 KMT2A (0.50) L3MBTL1ALDH1A1MEN1GAAKMT2A
Clopyralid SCHEMBL54779 0.70 KMT2A (0.50) L3MBTL1ALDH1A1MEN1GAAKMT2A
Clopyralid SCHEMBL8535196 0.70 KMT2A (0.50) L3MBTL1ALDH1A1MEN1GAAKMT2A
SCHEMBL14961901 0.70 HCAR3 (0.43) HCAR3ALDH1A1MEN1KMT2A
Clopyralid SCHEMBL2403527 0.69 KMT2A (0.49) L3MBTL1ALDH1A1MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
CN-101379036-B Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE 2011-06-01 CN disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
CN-101379036-A Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE (CH) 2009-03-04 CN disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC HCAR3 990/4885L3MBTL1 4869/4885ALDH1A1 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.